Application of lipid nanovesicle drug delivery system in cancer immunotherapy

Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yinan, Wang, Luhong, Li, Han, Miao, Fengqin, Zhang, Zhiyuan, Hu, Chunmei, Yu, Weiping, Tang, Qiusha, Shao, Guoliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073823/
https://www.ncbi.nlm.nih.gov/pubmed/35524277
http://dx.doi.org/10.1186/s12951-022-01429-2
_version_ 1784701372518629376
author Ding, Yinan
Wang, Luhong
Li, Han
Miao, Fengqin
Zhang, Zhiyuan
Hu, Chunmei
Yu, Weiping
Tang, Qiusha
Shao, Guoliang
author_facet Ding, Yinan
Wang, Luhong
Li, Han
Miao, Fengqin
Zhang, Zhiyuan
Hu, Chunmei
Yu, Weiping
Tang, Qiusha
Shao, Guoliang
author_sort Ding, Yinan
collection PubMed
description Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines. Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy. Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future.
format Online
Article
Text
id pubmed-9073823
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90738232022-05-06 Application of lipid nanovesicle drug delivery system in cancer immunotherapy Ding, Yinan Wang, Luhong Li, Han Miao, Fengqin Zhang, Zhiyuan Hu, Chunmei Yu, Weiping Tang, Qiusha Shao, Guoliang J Nanobiotechnology Review Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines. Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy. Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future. BioMed Central 2022-05-06 /pmc/articles/PMC9073823/ /pubmed/35524277 http://dx.doi.org/10.1186/s12951-022-01429-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ding, Yinan
Wang, Luhong
Li, Han
Miao, Fengqin
Zhang, Zhiyuan
Hu, Chunmei
Yu, Weiping
Tang, Qiusha
Shao, Guoliang
Application of lipid nanovesicle drug delivery system in cancer immunotherapy
title Application of lipid nanovesicle drug delivery system in cancer immunotherapy
title_full Application of lipid nanovesicle drug delivery system in cancer immunotherapy
title_fullStr Application of lipid nanovesicle drug delivery system in cancer immunotherapy
title_full_unstemmed Application of lipid nanovesicle drug delivery system in cancer immunotherapy
title_short Application of lipid nanovesicle drug delivery system in cancer immunotherapy
title_sort application of lipid nanovesicle drug delivery system in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073823/
https://www.ncbi.nlm.nih.gov/pubmed/35524277
http://dx.doi.org/10.1186/s12951-022-01429-2
work_keys_str_mv AT dingyinan applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT wangluhong applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT lihan applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT miaofengqin applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT zhangzhiyuan applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT huchunmei applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT yuweiping applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT tangqiusha applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy
AT shaoguoliang applicationoflipidnanovesicledrugdeliverysystemincancerimmunotherapy

Ejemplares similares